Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**Chromosome 20 open reading frame 202** (C20orf202) is a protein-coding gene in humans, encoding a nuclear protein of 122 amino acids primarily expressed in the lung and placenta[2][1]. The protein contains the conserved PFAM domain DUF3461, but its function remains unknown[2][5]. C20orf202 does not belong to any well-defined molecular class such as receptor, enzyme, or transporter, and is currently considered "uncharacterized" with no established biological function or drug interactions[2][1][12][14]. Moderate expression across tissues is noted, with fetal upregulation in kidney, lung, and intestine[2][15]. Its clinical relevance is limited but has been linked by association studies to Twin-To-Twin Transfusion Syndrome, Body Dysmorphic Disorder, and Multiple Sclerosis[1][2]. Protein-protein interaction studies predict binding to SNAPAP and HNRNPCL1, but these do not establish C20orf202 as a therapeutic target or biomarker at present[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chromosome 20 open reading frame 202 (C20orf202).